U.S. Markets closed

DURECT Corporation (DRRX)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
1.63-0.01 (-0.61%)
At close: 4:00PM EDT
People also watch
PTIEARQLDEPOCPRXGTXI
Full screen
Previous Close1.64
Open1.60
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.60 - 1.68
52 Week Range0.74 - 1.92
Volume322,375
Avg. Volume665,743
Market Cap231.41M
Beta2.05
PE Ratio (TTM)-6.29
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents5 days ago

    Edited Transcript of DRRX earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 DURECT Corp Earnings Call

  • Zacks Small Cap Research9 days ago

    DRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United States

    On May 8, 2017, Durect (DRRX) announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States Durect’s POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. Under the terms of the agreement, Sandoz will make an upfront payment to DURECT of $20 million, with the potential for up to an additional $43 million in development and regulatory milestones, up to an additional $230 million in sales based milestones, as well as a tiered double digit royalty on product sales in the United States. The $43 million could be received when Durect resubmits the NDA and get approval for Posimir which could be done in 1Q18.

  • Associated Press11 days ago

    Durect reports 2Q loss

    On a per-share basis, the Cupertino, California-based company said it had a loss of 7 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...